(Q44801525)

6 December 2017

1 reference

title

Newer oral contraceptives and the risk of venous thromboembolism (English)

1 reference

6 December 2017

venous thromboembolism

1 reference

A M Walker

1

1 reference

PubMed ID

9617533

6 December 2017

language of work or name

1 reference

1 March 1998

1 reference

6 December 2017

1 reference

6 December 2017

57

1 reference

6 December 2017

3

1 reference

6 December 2017

169-181

1 reference

Oral contraceptives and venous thromboembolism

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. Description and validation of methods. World Health Organization Collaborative Study of Cardiovascular and Steroid Hormone Contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Interim review of the Transnational Case-control Study of Oral Contraceptives and Health: approved protocol revisions through September 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Bias in studies of venous thromboembolism in relation to the use of new formulations of oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Risk of oral contraceptives and recency of market introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

First-time use of newer oral contraceptives and the risk of venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Population-based study of risk of venous thromboembolism associated with various oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Third-generation oral contraceptives and venous thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Third-generation oral contraceptives and venous thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

The role of prescribing and referral bias in studies of the association between third generation oral contraceptives and increased risk of thromboembolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Selective prescribing of third generation oral contraceptives (OCs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Recent oral contraceptive use patterns in four European countries: evidence for selective prescribing of oral contraceptives containing third-generation progestogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Mortality from venous thromboembolism and myocardial infarction in young adults in England and Wales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Oral contraceptives and mortality from venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Mortality from venous thromboembolism among young women in Europe: no evidence for any effect of third generation oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

End of the line for "third-generation-pill" controversy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Oral contraceptives and thrombotic diseases: impact of new epidemiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Modern oral contraceptives and cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Estrogen and progestin components of oral contraceptives: relationship to vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Thromboembolic Disease and the Steroidal Content of Oral Contraceptives. A Report to the Committee on Safety of Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Investigation of relation between use of oral contraceptives and thromboembolic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

Third-generation oral contraceptives and venous thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2898%2900014-6

10.1016/S0010-7824(98)00014-6

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference

PubMed ID

9617533